| HS Code | 808833 |
| Productname | Duck Plague Vaccine, Live Veterinary Grade API |
| Producttype | Live Attenuated Viral Vaccine |
| Viralpathogen | Anatid Alphaherpesvirus 1 (Duck Enteritis Virus) |
| Targetspecies | Ducks and Geese |
| Indication | Active Immunization Against Duck Plague (Duck Viral Enteritis) |
| Aiphysicalform | Lyophilized Powder or Frozen Liquid |
| Solubility | Reconstitutable or Formulatable in Sterile Water, Buffers, or Excipient Systems |
| Dosageformssupported | Tablets, Injections, Capsules, Powders, Granules, Premix, Solutions |
| Administrationroutes | Oral, Subcutaneous, Intramuscular |
| Vaccinetypederivation | Attenuated Live Virus for Induction of Humoral and Cell-Mediated Immunity |
| Storagetemperature | 2 to 8 °C; Long-Term Lyophilized Storage at -20 °C or Below |
| Lightsensitivity | Protect from Direct Light and UV Exposure |
| Shelflife | 12 to 24 Months Depending on Final Formulation |
| Withdrawalperiod | Zero Days for Poultry |
| Biosecurityprecaution | Avoid Heat, Strong Disinfectants, and Freeze-Thaw Cycles to Preserve Live Virus Potency |
As an accredited Duck Plague Vaccine,Live Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | Lyophilized live Duck Plague Vaccine, veterinary grade API. Supplied in sealed 100-dose vials for tablet, injection, or powder formulations. |
| Container Loading (20′ FCL) | One 20′ FCL container loaded with live veterinary-grade Duck Plague Vaccine API, securely packed for tablets, injections, capsules, powders, granules, premix, and solutions. |
| Shipping | Ship as temperature-controlled live veterinary vaccine API. Pack in validated insulated containers with gel packs or dry ice, maintaining 2–8°C (or per label). Use sterile, sealed, moisture-proof primary packaging suitable for tablets, injections, capsules, powders, granules, premix, or solutions. Protect from light, freeze, and breakage. Include temperature loggers and expedited delivery. |
| Storage | Store under strict cold chain at 2–8°C, protected from light and moisture. Do not freeze or expose to high temperatures. Keep in original airtight containers, away from disinfectants and oxidizing agents. Use aseptic handling to prevent contamination. Follow veterinary guidelines; avoid repeated temperature fluctuations to maintain live-virus potency and efficacy. |
| Shelf Life | Shelf life refers to the period the live vaccine remains potent under recommended cold storage, typically 12–24 months before expiry. |
At the bulk drug substance stage, live duck enteritis virus is handled as a stabilizer-supplemented, clarified allantoic fluid or cell-culture supernatant rather than as a dry chemical powder. The target agent, Anatid alphaherpesvirus 1, is an enveloped DNA virus with reported particle diameters in the 120–180 nm range and a half-life that falls sharply when the virus is exposed to pH values below 6.0, chlorine residuals above 0.1 mg/L, or shear stress generated by high-pressure homogenization. Downstream manufacturing therefore excludes direct compression, roller compaction, wet granulation, and fluid-bed drying because the thermal and mechanical inputs associated with these unit operations—compression pressures above 35 MPa and inlet air temperatures above 35°C—are sufficient to reduce infectivity below the minimum release titre in bulk antigen spike runs. The applicable veterinary biological safety framework derives from 9 CFR Part 113, with final container sterility confirmed by 9 CFR 113.27 or 21 CFR 610.12; mycoplasma absence is controlled under 9 CFR 113.35 and Ph. Eur. 2.6.7. The API is not a candidate for tablet, capsule, granule, or feed premix presentations because the live virion must remain hydrated or vitrified within a cryoprotectant matrix to retain the titre required for flock immunity.
Lyophilization of the stabilized liquid virus into a 1–3% residual-moisture cake is the principal commercial presentation for parenteral vaccination. The process begins with filling sterile Type I glass vials to a nominal liquid fill volume of 1.0–5.0 mL, followed by partial stoppering and loading onto a production freeze dryer with shelf area not less than 10 m² and condenser capacity matched to a total batch sublimation load above 25 kg. The freezing ramp is controlled at 0.5°C/min to a minimum product temperature of -45°C because rapid uncontrolled nucleation produces intracellular ice damage in residual host-cell debris and alters the virion envelope glycoprotein conformation. Primary drying is executed at a shelf temperature of -20°C ± 2°C and chamber pressure of 80–150 µbar for 18–24 h; these conditions are selected to keep product temperature below the collapse temperature, which is typically identified by freeze-dry microscopy in the range of -28°C to -22°C for sucrose-gelatin formulations. If product temperature exceeds the collapse boundary by more than 1°C, the dried cake shrinks, reconstitution time extends beyond 60 s, and infectivity titre loss can exceed 0.5 log₁₀ TCID₅₀ per vial. Secondary drying at +20°C for 4–6 h lowers residual moisture to the release range; moisture content is checked by Karl Fischer coulometry according to USP <921> or an equivalent validated method.
When the freeze-dried cake is intended for mass drinking-water administration, the diluent compatibility envelope changes substantially relative to sterile phosphate-buffered saline injection. Field water in commercial duck sheds frequently contains residual chlorine 0.2–2.0 mg/L, dissolved iron or manganese, and variable bicarbonate alkalinity; each parameter is measured before vaccine addition because the live herpesvirus envelope is inactivated by oxidative disinfectants and by pH excursions above 8.0 or below 6.5. The reconstituted vaccine is added to non-chlorinated water containing 2–5 g/L skim milk powder or a certified stabilizer sachet to bind trace sanitizers and protect the virion during passage through the crop and proventriculus. Water is withheld for 1–2 h to generate uniform drinking activity, and the entire medicated water volume is consumed within 2 h, because titre in unstabilized water declines by at least 0.3 log₁₀ TCID₅₀ per hour at 25°C. Published data for the exact dose equivalence between drinking-water and parenteral routes in duck enteritis virus is limited; batch-specific immunogenicity testing under the target water quality is therefore required before a label claim can be extended.
Hatchery spray vaccination is applied to day-old ducks when individual injection would create an unacceptable bottleneck at throughputs above 5,000 birds per hour. The reconstituted vaccine is loaded into a spray cabinet fitted with rotary atomizers or nozzle arrays calibrated to produce a droplet median diameter of 80–150 µm and a delivery volume of 0.20–0.50 mL per bird, because smaller droplets drift away from the target flock and larger droplets run off the plumage before mucosal contact. The vaccinating fluid must be maintained at 15–25°C during the run; chilled fluid below 10°C reduces the speed of eye or nasal contact and increases the number of unvaccinated birds. Equipment validation follows the principles of ISO 13408-1:2008 for aseptic processing because the live virus cannot be filtered through a 0.2 µm sterilizing-grade membrane; the entire spray circuit is sanitized and rinsed with chlorine-free water before and after use. The droplet size distribution is confirmed with a laser diffraction analyzer after each nozzle change. Published production data for this specific configuration in duck plague vaccination is limited, so a dye-tracer coverage audit is performed using 0.1% fluorescein sodium in the spray volume to measure beak and head coverage before routine use.
The stabilizer system in a live duck plague vaccine is not an inert filler; it performs three simultaneous functions: cryoprotection during freezing, vitrification during primary drying, and buffering after reconstitution. A sucrose-gelatin matrix contains sucrose at 5–10% w/v, hydrolyzed gelatin at 1–2% w/v, and monosodium glutamate at 0.1–0.5% w/v; the combination depresses the glass transition temperature of the maximally freeze-concentrated solute to approximately -33°C and creates a glassy matrix with residual moisture of 1–3% after secondary drying. Differential scanning calorimetry and freeze-dry microscopy are used to establish the thermal design space for each new harvest lot, because host-cell protein and lipid carryover from different egg or cell lots can shift the collapse temperature by 1–3°C. Bulk frozen intermediates, in contrast, are stored at -70°C ± 5°C in 1 mL cryovials or 50 mL conical tubes with no more than 80% fill volume; repeated freeze-thaw cycling beyond 3 cycles reduces titre by at least 0.5 log₁₀ EID₅₀. The frozen bulk is not subjected to sterile filtration, so aseptic processing begins at the point of harvest and is maintained under ISO 14644-1:2015 class A unidirectional airflow with class B background.
| Route / Form | Critical equipment | Measured parameter | Acceptance window |
|---|---|---|---|
| Freeze-dried cake | Lyophilizer with condenser | Residual moisture by Karl Fischer | 1.0–3.0% |
| Drinking-water solution | Chlorine-free water line | Free chlorine | ≤0.1 mg/L |
| Hatchery spray | Rotary atomizer spray cabinet | Droplet Dv50 | 80–150 µm |
| Reconstituted injection | Repeating syringe | Delivered volume | 0.50 mL ± 0.05 mL |
Compatibility of the live virus with non-standard diluents becomes critical when a producer supplies only the lyophilized cake and permits field dilution in local potable water. The risk of using non-sterile water is not primarily bacterial contamination but rather the presence of metal ions, carbonate alkalinity, and disinfectant residues that destabilize the virion envelope before injection or oral administration. If the measured free chlorine concentration exceeds 0.1 mg/L, sodium thiosulfate is dosed at 16 mg/L per 1 mg/L chlorine equivalent and the water is retested before vaccine addition; however, sodium thiosulfate is not compatible with oxidant-sensitive live virus if overdosed, so the final pH is adjusted to 6.8–7.4 with citrate buffer rather than phosphate buffer that can precipitate with calcium in hard water. For parenteral use in small flocks, the manufacturer-supplied sterile diluent is used without substitution because commercial saline or Ringer’s lactate solutions may contain preservatives or calcium concentrations above 2 mmol/L that reduce virus stability over the 2 h in-use period. Needles with 21G or 22G are preferred over 25G because the viscosity of the rehydrated stabilizer can exceed 2.5 mPa·s and cause shear damage in narrow-bore needles during rapid injection. Each batch of field dilution water is sampled and tested according to a site-specific plan aligned with ISO 22519:2019 for purified water and water for injection system monitoring.
Direct compression of the live virus into tablets or capsules is not a valid veterinary application because the operability window for tableting exceeds the biological tolerance of the enveloped virion. Rotary tablet presses operate at dwell times below 300 ms and compaction pressures commonly above 40 MPa; these stresses, combined with die wall temperatures up to 40°C, reduce live herpesvirus titre by more than 2.0 log₁₀ TCID₅₀ even when lyophilized excipients such as mannitol and sorbitol are used. Capsule filling introduces electrostatic charge and dry powder segregation, while granulation requires water addition and drying at 35–50°C that can be incompatible with live virus. Feed premixes and granules are similarly excluded because pellet conditioning at 70–85°C and high-moisture steam injection denature the virion before ingestion. A liquid oral solution is possible only when stabilizer is present and the pH is buffered; without these components, the half-life of the virus at room temperature is less than 60 min.
Competitive Duck Plague Vaccine,Live Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8615365186327 or mail to admin@ascent-chem.com.
We will respond to you as soon as possible.
Tel: +8615365186327
Email: admin@ascent-chem.com
Flexible payment, competitive price, premium service - Inquire now!
Duck Plague Vaccine, Live Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is a lyophilised live attenuated virus active pharmaceutical ingredient derived from duck viral enteritis virus, also identified as anatid alphaherpesvirus 1. The material is not a chemically synthesised small molecule; potency depends on survival of replication-competent virus through downstream formulation, packaging, and administration. The product is intended for incorporation into multiple veterinary dosage presentations, including tableted baits, injectable diluents, capsules, dry powders, granules, premixes, and drinking-water solutions. Because the live virus is thermolabile, shear-sensitive, and pH-sensitive, downstream processing boundaries are more restrictive than those applied to conventional crystalline or amorphous chemical APIs. In the lyophilised state, the virus is embedded in a glassy stabiliser matrix, usually composed of sucrose, dextran, or an authorised protein hydrolysate. That matrix functions as both protective carrier and the principal source of tableting and granulation process constraints.
Model identification for this API follows the manufacturer’s veterinary biologics establishment licence and the relevant drug master file. Unlike a small-molecule API, where the model may specify polymorphic form and particle-size distribution, the live duck plague API is defined by seed lot identity, passage history, stabiliser composition, residual moisture after lyophilisation, and the intended final dosage form. The compendial identity is Duck viral enteritis vaccine, live, while the downstream processing grade may be direct compression grade, sterile injection grade, or oral premix grade. The claimed utility across tablets, injections, capsules, powders, granules, premixes, and solutions is therefore not a single universal chemical entity but a controlled biological matrix that must be revalidated for each formulation route.
Release specifications for the bulk API are virus-centred rather than purity-centred. Identity is confirmed by virus neutralisation or by amplification of anatid alphaherpesvirus 1-specific nucleic acid. Potency is expressed as median tissue culture infectious dose or median embryo infectious dose; the minimum release titre is seed-specific and set by the marketing authorisation. Sterility, bacterial endotoxin, water content, reconstituted pH, and cake appearance are supplementary release parameters. No universal numerical potency value is assigned across all live duck plague vaccines. The WOAH Terrestrial Manual 2021, Chapter 3.3.6 describes the general production and testing approach, but the registered titre remains product-specific.
Control of live duck plague vaccine API requires an orthogonal set of biological tests because conventional chemical purity specifications do not capture infectivity loss. Sterility is determined by membrane filtration or direct inoculation into soybean-casein digest and fluid thioglycollate media under USP <71> conditions. Endotoxin is measured by limulus amebocyte lysate assay under USP <85>; the limit is route-specific, with a parenteral dosage requiring a tighter limit than an oral powder. Water content is measured by Karl Fischer coulometric titration under USP <921>. The pH of the reconstituted product is checked against the registered specification because pH shifts outside the registered range can destabilise the viral envelope glycoproteins. Cake appearance is inspected visually for meltback, collapse, and colour change, which are early indicators of lyophilisation failure.
| Control parameter | Typical analytical target | Reference method |
|---|---|---|
| Identity | specific amplification product or neutralisation with reference antiserum | WOAH Terrestrial Manual 2021, Chapter 3.3.6 |
| Potency | live virus titre in TCID50 or EID50; minimum release titre is registration-specific | WOAH Terrestrial Manual 2021, Chapter 3.3.6, vaccination-challenge in susceptible ducklings |
| Sterility | no growth in soybean-casein digest and fluid thioglycollate media | USP <71> |
| Bacterial endotoxins | route-specific limit justified by injectable dose; oral powders may not require compendial endotoxin testing unless specified | USP <85> |
| Water content | registered limit, usually ≤3.0% w/w for lyophilised live viral cake | USP <921> |
| Reconstituted pH | typically 6.5–7.5; registration-specific | USP <791> |
| Cake appearance | intact, uniform, no collapse or meltback | visual inspection |
At production scale, residual moisture variation in the lyophilised API is principally controlled by secondary drying shelf temperature, chamber pressure, and cycle duration. A collapse or microcollapse event during primary drying can reduce the virus titre by as much as 1 log10 in the affected cake fraction, and the resulting moisture pockets can accelerate degradation during storage. Production freeze-dryers with shelf temperature ramps between -40°C and +20°C are normally used. Chamber pressure is maintained below 200 μbar during primary drying to avoid collapse. The actual collapse temperature of a given duck plague API formulation is influenced by the stabiliser system and viral concentration; published data for this specific live duck plague antigen matrix are limited, so lyophilisation cycle qualification on the production freeze-dryer is required before batch release.
When the API is directed into tableted or encapsulated dose forms, the primary risk is loss of viable virus due to compaction energy and localised heat. Direct compression with directly compressible mannitol and microcrystalline cellulose is preferred over wet granulation because aqueous granulation fluid reactivates the glassy matrix and exposes the virus to shear and thermal stress. Tablet compression at pressures above 120 MPa should not be assumed safe for live viral vaccine tablets; published data specific to tableted duck plague live API are limited, so feasibility batches must include virus titre recovery after compression. Magnesium stearate as a tablet lubricant is typically limited to ≤0.5% w/w because excessive lubricant can reduce tablet tensile strength and increase the need for higher compression force. Capsule filling is less damaging than tablet compression when low-fill-weight dosators are used, but the capsule fill must be protected from atmospheric humidity above 60% relative humidity during filling and storage.
Granulation of the lyophilised API prior to compression is generally incompatible with live virus integrity. If a granulated intermediate is required for low-dose uniformity, dry roller compaction may be evaluated at roll force not exceeding 5 kN/cm; however, virus titre must be measured across each granule size fraction because dry granulation can generate fines with reduced activity. Coated tablet development should avoid organic solvents and enteric coatings that require sustained heat, because live duck plague virus titre may decline rapidly above 30°C unless the API is in a moisture-barrier package. Tablet hardness, friability, and disintegration should be tested by compendial methods; the critical release criterion remains virus titre recovery after the compression step.
Reconstitution of the lyophilised API into injectable or drinking-water solutions requires sterile diluents without antiviral preservatives. Thiomersal, benzalkonium chloride, chlorocresol, and oxidising agents are incompatible with live duck plague virus and must not be added to the diluent. The lyophilised cake is reconstituted to the intended dose volume, and the reconstituted solution is held under validated conditions. The in-use hold time at 2–8°C for reconstituted live viral vaccines is commonly no more than 4 h; after this period, virus titre may fall below the release limit. Filtration through sterilising-grade 0.22 μm filters may remove viral aggregates and reduce recoverable titre by more than 0.5 log10. If filtration is required for aseptic processing, the pre-filtration titre must be adjusted to compensate for the measured loss. Aseptic filling is conducted in an ISO 14644-1:2015 Class 7 or higher environment using low-shear peristaltic pumps and single-use filling needles.
Terminal sterilisation by autoclaving, gamma irradiation, or ethylene oxide is not applicable to this live biological API because these processes inactivate the virus. The filling line must therefore be designed for aseptic assembly and disassembly, and product-contact surfaces must be cleaned without steam or hot water above 40°C. Residual moisture in the lyophilised cake influences reconstitution time; a collapsed cake or a cake with excessive moisture may not completely dissolve and may produce visible particles in solution. For injection, the final solution should be visually inspected for particulate matter and tested according to USP <788> where the registered presentation is a parenteral solution.
Powder, granule, and premix formats for oral administration are produced by blending the lyophilised API with spray-dried lactose, sucrose, or dextrose carriers in low-shear V-blenders or bin blenders. The blending speed and fill volume are selected to minimise particle impaction and attrition, since the virus-enriched particles are not free-flowing crystalline solids. Powder segregation is controlled by matching the particle-size distribution of the API and carrier. Lyophilised cake after coarse comminution typically exhibits a mass median diameter above 100 μm; air-jet micronisation is not recommended because mechanical energy and local temperature rise can reduce virus titre. Effervescent granules are incompatible with live duck plague vaccine because the resulting pH and ionic strength can inactivate the virus. Water-soluble granulations may be prepared by low-moisture wet massing or dry roller compaction with immediate drying below 30°C. Equipment cleaning should avoid hot water at or above 40°C because residual heat on contact surfaces can reduce viability of the next batch.
Stability testing of the lyophilised live API and its formulated presentations follows the general principles of VICH GL51. Registration batches are placed on real-time stability at 2–8°C and monitored for virus titre, moisture, pH, and visual appearance. Accelerated storage above 25°C is often not informative for live duck plague vaccine presentations because thermal inactivation may be too rapid to support extrapolation. Water-barrier packaging is used for tablets, capsules, and powders; desiccants are added only after compatibility with the lyophilised cake is confirmed, because certain desiccants may produce localised heat or acidic surface behaviour.
Handling of the live API follows facility biosafety risk assessment and national veterinary biologics regulations. Spills and product-contact surfaces are decontaminated with an approved virucidal agent after the active material has been removed. Disinfectant selection must not overlap with production equipment cleaning, because chlorinated oxidising agents and quaternary ammonium compounds are suitable for decontamination but are incompatible with any residual live virus in the next formulation batch if not completely rinsed.
The live duck plague API differs from inactivated whole-virus vaccines and chemical antiviral agents in three operational respects: the potency unit is virus titre rather than mass, terminal sterilisation is contraindicated, and downstream processing must preserve the glassy viral matrix. Inactivated duck plague vaccines typically contain adjuvants and may tolerate preservatives that are lethal to live virus. Chemically synthesised small-molecule APIs are often crystalline or spray-dried powders that can be granulated, compressed, or hot-melt extruded without regard to viral infectivity. For the live API, every unit operation downstream of lyophilisation is a potential inactivation step, and the acceptable operating window is narrow.
| Control attribute | Live duck plague API | Inactivated whole-virus duck plague vaccine | Chemically synthesised small-molecule antiviral API |
|---|---|---|---|
| Active agent | live attenuated anatid alphaherpesvirus 1 | inactivated whole virus, typically with adjuvant | defined chemical entity; no replication |
| Potency unit | TCID50 or EID50 | antigen mass or potency relative to reference vaccine in challenge model | mass purity, assay by HPLC or LC-MS |
| Thermal tolerance | fragile; store at 2–8°C unless otherwise validated | more stable but may still require cold chain with adjuvant | often stable at 25°C or 40°C according to ICH Q1A(R2) storage conditions |
| Terminal sterilisation | not possible; live virus inactivated by autoclave, gamma, or ethylene oxide | terminal filtration possible only after antigen inactivation; adjuvants may restrict | terminal sterilisation or aseptic processing possible depending on heat sensitivity |
| Downstream processing | lyophilisation, low-shear blending, no hot-melt extrusion, no aqueous granulation | adjuvant mixing, emulsion stabilisation, aseptic filling | granulation, compression, hot-melt extrusion, and spray drying possible |
| Excipient compatibility | avoid preservatives, oxidising agents, high ionic strength, pH below 6.0 or above 8.0 | adjuvant compatibility dominates; preservatives may be allowed in killed vaccines | compatibility governed by chemical degradation pathways |
At production scale, the main batch-to-batch variability is observed in lyophilisation rather than in powder blending. Sublimation rate differences across shelf positions can produce edge-vial cake collapse when the thermal load is not uniform; therefore batch release should include review of lyophilisation chamber pressure, shelf temperature, and cold-trap temperature records against the qualified freeze-drying recipe. In tablet or granulation operations, the live virus is not a free-flowing crystalline material, and the downstream equipment train must be designed for low-shear transfer, low-temperature drying, and humidity-controlled packaging. Published data for advanced tablet or capsule formulations containing this specific live duck plague API remain limited, so formulation feasibility should be established by sequential virus titre recovery studies after each unit operation.
